Last updated on May 2020

A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)


Brief description of study

This study aims to obtain plasma pharmacokinetic (PK) data and characterize the PK profile of imipenem (IMI), cilastatin (CIL), and relebactam (REL) following administration of a single intravenous (IV) dose of MK-7655A (a fixed ratio combination of imipenem/cilastatin/relebactam), hereafter referred to as IMI/REL.

Clinical Study Identifier: NCT03230916

Find a site near you

Start Over

Arkansas Children's Hospital ( Site 1311)

Little Rock, AR United States
2.33miles
  Connect »